Cellivery Therapeutics Inc
KOSDAQ:268600
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Balance Sheet
Balance Sheet Decomposition
Cellivery Therapeutics Inc
| Current Assets | 5.7B |
| Cash & Short-Term Investments | 589.8m |
| Receivables | 1.8B |
| Other Current Assets | 3.3B |
| Non-Current Assets | 20.2B |
| Long-Term Investments | 1.1B |
| PP&E | 17.8B |
| Intangibles | 438.8m |
| Other Non-Current Assets | 957.6m |
| Current Liabilities | 53.9B |
| Accounts Payable | 2.9B |
| Accrued Liabilities | 6.5B |
| Short-Term Debt | 16.1B |
| Other Current Liabilities | 28.4B |
| Non-Current Liabilities | -725.6m |
| Long-Term Debt | 368.7m |
| Other Non-Current Liabilities | -1.1B |
Balance Sheet
Cellivery Therapeutics Inc
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
1 125
|
85
|
3 471
|
983
|
1 245
|
28 679
|
1
|
14 578
|
1 459
|
|
| Cash |
0
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
1 459
|
|
| Cash Equivalents |
1 125
|
85
|
3 470
|
983
|
1 245
|
28 679
|
0
|
14 578
|
0
|
|
| Short-Term Investments |
1 500
|
0
|
2 550
|
35 846
|
26 138
|
25 135
|
15 744
|
50
|
0
|
|
| Total Receivables |
9
|
124
|
320
|
661
|
553
|
301
|
5 538
|
6 811
|
3 242
|
|
| Accounts Receivables |
0
|
105
|
119
|
539
|
377
|
0
|
4 695
|
4 476
|
1 193
|
|
| Other Receivables |
0
|
19
|
201
|
122
|
176
|
0
|
843
|
2 334
|
2 049
|
|
| Inventory |
0
|
43
|
153
|
59
|
0
|
0
|
3 920
|
6 539
|
2 924
|
|
| Other Current Assets |
83
|
52
|
293
|
92
|
429
|
543
|
3 858
|
1 581
|
223
|
|
| Total Current Assets |
2 717
|
303
|
6 786
|
37 641
|
28 364
|
54 658
|
98 385
|
29 558
|
7 847
|
|
| PP&E Net |
1 020
|
1 350
|
1 290
|
1 436
|
1 587
|
2 705
|
24 130
|
39 064
|
19 487
|
|
| PP&E Gross |
0
|
0
|
1 290
|
1 436
|
1 587
|
2 705
|
24 130
|
39 064
|
19 487
|
|
| Accumulated Depreciation |
0
|
0
|
875
|
1 368
|
2 322
|
2 642
|
11 665
|
14 133
|
18 702
|
|
| Intangible Assets |
10
|
144
|
27
|
36
|
292
|
545
|
2 931
|
844
|
472
|
|
| Note Receivable |
259
|
247
|
0
|
277
|
0
|
282
|
883
|
11 701
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
1 970
|
3 124
|
3 052
|
1 135
|
|
| Other Long-Term Assets |
34
|
161
|
329
|
606
|
615
|
357
|
388
|
485
|
1 221
|
|
| Total Assets |
4 041
N/A
|
2 205
-45%
|
8 433
+282%
|
39 995
+374%
|
30 858
-23%
|
60 516
+96%
|
129 841
+115%
|
84 705
-35%
|
30 164
-64%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
0
|
2 209
|
1 225
|
261
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5 301
|
|
| Short-Term Debt |
100
|
57
|
0
|
0
|
0
|
0
|
9 114
|
14 071
|
16 524
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
5 483
|
0
|
167
|
362
|
11 833
|
30 149
|
28 947
|
|
| Other Current Liabilities |
8 471
|
22 194
|
23 709
|
3 393
|
1 916
|
899
|
2 991
|
9 678
|
3 592
|
|
| Total Current Liabilities |
8 571
|
22 251
|
29 192
|
3 393
|
2 084
|
1 261
|
26 147
|
55 123
|
54 625
|
|
| Long-Term Debt |
4 449
|
6 586
|
6 686
|
0
|
0
|
20 721
|
23 639
|
18 539
|
748
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
231
|
1 698
|
|
| Other Liabilities |
158
|
320
|
559
|
777
|
1 491
|
141
|
5 049
|
588
|
958
|
|
| Total Liabilities |
13 178
N/A
|
29 157
+121%
|
36 438
+25%
|
4 170
-89%
|
3 575
-14%
|
22 123
+519%
|
54 834
+148%
|
74 019
+35%
|
54 633
-26%
|
|
| Equity | ||||||||||
| Common Stock |
683
|
1 367
|
1 849
|
3 806
|
3 910
|
4 207
|
9 026
|
18 342
|
18 396
|
|
| Retained Earnings |
10 237
|
28 069
|
43 059
|
50 354
|
70 262
|
87 511
|
115 446
|
190 605
|
223 176
|
|
| Additional Paid In Capital |
417
|
267
|
13 204
|
82 373
|
93 636
|
121 698
|
172 026
|
168 006
|
169 953
|
|
| Other Equity |
0
|
17
|
0
|
0
|
0
|
0
|
9 402
|
14 943
|
10 358
|
|
| Total Equity |
9 137
N/A
|
26 952
-195%
|
28 005
-4%
|
35 826
N/A
|
27 283
-24%
|
38 393
+41%
|
75 007
+95%
|
10 686
-86%
|
24 469
N/A
|
|
| Total Liabilities & Equity |
4 041
N/A
|
2 205
-45%
|
8 433
+282%
|
39 995
+374%
|
30 858
-23%
|
60 516
+96%
|
129 841
+115%
|
84 705
-35%
|
30 164
-64%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
5
|
5
|
7
|
15
|
16
|
17
|
35
|
36
|
37
|
|
| Preferred Shares Outstanding |
3
|
3
|
2
|
0
|
0
|
0
|
1
|
0
|
0
|
|
You don't have any saved screeners yet
